ribavirin has been researched along with Congenital Zika Syndrome in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Brzuska, G; Ferry, A; Gallier, F; Gonzalez, S; Krol, E; Lubin-Germain, N; Ouarti, A; Solarte, C; Uziel, J | 1 |
| Betancur-Galvis, LA; Brand, YM; González-Cardenete, MA; González-Zapata, N; Hamulić, D; Jimenez-Jarava, OJ; Marín, ML; Martinez-Gutierrez, M; Miquel-Leal, FJ; Restrepo-Mendez, LC | 1 |
| Falk, A; Helleday, T; Mirazimi, A; Pettke, A; Pronk, R; Puumalainen, MR; Tampere, M; Wallner, O; Warpman Berglund, U | 1 |
| Aliota, MT; Bonnac, LF; Geraghty, RJ | 1 |
| Baz, M; Boivin, G; Goyette, N; Griffin, BD; Kobinger, GP | 1 |
| Eshita, Y; Fukuda, C; Gendo, Y; Hidano, S; Kamiyama, N; Kobayashi, T; Matsubara, E; Miura, Y; Noguchi, K; Ozaki, T; Runtuwene, LR; Sachi, N; Soma, R; Sonoda, A; Tajima, S; Takasaki, T; Umekita, H; Watanabe, K | 1 |
| Brown, AN; Bulitta, JB; Kim, TH; Pires de Mello, CP; Pomeroy, JJ; Rodriquez, JL; Tao, X | 1 |
| Kim, JA; Kumar, M; Seong, RK; Shin, OS | 1 |
| Arias, A; Bassi, MR; Meyn, P; Polacek, C; Sempere, RN | 1 |
| Adcock, RS; Chu, YK; Chung, DH; Golden, JE | 1 |
3 review(s) available for ribavirin and Congenital Zika Syndrome
| Article | Year |
|---|---|
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |
Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
Topics: Abietanes; Antiviral Agents; Chikungunya virus; Humans; Virus Replication; Viruses; Zika Virus; Zika Virus Infection | 2022 |
Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; COVID-19 Drug Treatment; Hemorrhagic Fever, Ebola; Humans; Middle East Respiratory Syndrome Coronavirus; Mutagenesis; Nucleosides; Pyrazines; Ribavirin; SARS-CoV-2; Virus Replication; Zika Virus; Zika Virus Infection | 2021 |
9 other study(ies) available for ribavirin and Congenital Zika Syndrome
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Hepacivirus; Hepatitis C; Humans; Nucleosides; Ribavirin; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2022 |
Broadly Active Antiviral Compounds Disturb Zika Virus Progeny Release Rescuing Virus-Induced Toxicity in Brain Organoids.
Topics: Animals; Antiviral Agents; Brain; Cell Survival; COVID-19; Humans; Organoids; Ribavirin; RNA Viruses; SARS-CoV-2; Zika Virus; Zika Virus Infection | 2020 |
In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin.
Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Drug Synergism; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Pyrazines; Ribavirin; Spatio-Temporal Analysis; Vero Cells; Zika Virus; Zika Virus Infection | 2017 |
Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; DNA Replication; Mice; Ribavirin; STAT1 Transcription Factor; Vero Cells; Viremia; Virus Replication; Zika Virus; Zika Virus Infection | 2017 |
Zika Virus Replication Is Substantially Inhibited by Novel Favipiravir and Interferon Alpha Combination Regimens.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; DNA Replication; Humans; Interferon-alpha; Pyrazines; Ribavirin; Vero Cells; Viral Load; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |
Favipiravir and Ribavirin Inhibit Replication of Asian and African Strains of Zika Virus in Different Cell Models.
Topics: Amides; Animals; Antiviral Agents; Apoptosis; Cell Line; Cell Proliferation; Chlorocebus aethiops; Humans; Pyrazines; Ribavirin; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |
Extinction of Zika Virus and Usutu Virus by Lethal Mutagenesis Reveals Different Patterns of Sensitivity to Three Mutagenic Drugs.
Topics: Amides; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Epithelial Cells; Flavivirus; Fluorouracil; Mutagenesis; Mutagens; Mutation Rate; Nucleosides; Pyrazines; Ribavirin; Ribonucleosides; Serial Passage; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |
Evaluation of anti-Zika virus activities of broad-spectrum antivirals and NIH clinical collection compounds using a cell-based, high-throughput screen assay.
Topics: Animals; Antiviral Agents; Azauridine; Biphenyl Compounds; Chlorocebus aethiops; Cytopathogenic Effect, Viral; Drug Discovery; High-Throughput Screening Assays; Humans; Ribavirin; Small Molecule Libraries; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2017 |